Supply Chain Intelligence

Syndax Pharmaceuticals, Inc. Supply Chain

SNDX supply chain intelligence for Syndax Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

SNDX ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

5Suppliers
2Customers
3Debt Items
20Related Chains

Syndax Pharmaceuticals, Inc. Suppliers

TickerNameConfidenceEvidence
UCB-BIOPHARMA-SRL UCB-BIOPHARMA-SRL 92% In 2016, the Company entered into a license agreement, or the UCB License Agreement, as amended from time to time, with UCB Biopharma Sprl, or UCB, under which UCB granted to the Company a worldwide,…
RPRX Royalty Pharma plc 90% the Purchase and Sale Agreement provides that if certain events of default occur, including certain bankruptcy events or certain termination events with respect to the Company’s license agreement wit…
RPRX Royalty Pharma plc 90% Reciprocal relationship from RPRX graph: Reciprocal relationship from SNDX graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from SNDX graph: the Purchase and Sale Agreement pro…
VITAE-LICENSE-AGREEMENT VITAE-LICENSE-AGREEMENT 85% As of the date of the Vitae License Agreement, the asset acquired had no alternative future use nor had it reached a stage of technological feasibility
ATNM Actinium Pharmaceuticals, Inc. 72% Reciprocal relationship from ATNM graph: Reciprocal relationship from SNDX graph: Reciprocal relationship from ATNM graph: Reciprocal relationship from SNDX graph: Reciprocal relationship from ATNM g…

Syndax Pharmaceuticals, Inc. Customers

TickerNameConfidenceEvidence
REVUFORJ REVUFORJ 80% We are leading the commercialization and further development of revumenib and working closely with our collaboration partner, Incyte, on the commercialization and further development of axatilimab
NIKTIMVO NIKTIMVO 75% the first United States sale of Revuforj in its second indication

Syndax Pharmaceuticals, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
SNDX-DEBT-12638 Xbrl Convertible 90% xbrl convertible detail from xbrl 2016-12-31.
SNDX-DEBT-12637 Warrants outstanding: 0.0001 90% xbrl warrant detail from xbrl 2019-03-31.
SNDX-DEBT Debt stack $345.4M 90% Market cache reports total debt of $345.4M.

Syndax Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Syndax Pharmaceuticals, Inc..

Syndax Pharmaceuticals, Inc. Ownership

HolderNameConfidenceEvidence
SNDX-OWNER-GOLDMAN-SACHS-GROUP-INC GOLDMAN SACHS GROUP INC 90% 13F overlay lists GOLDMAN SACHS GROUP INC as top holder; 246 tracked holders.

Syndax Pharmaceuticals, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
TKPHF Takeda Pharmaceutical Company Limited 100.00 2
PRLD Prelude Therapeutics Incorporated 100.00 2
ATNM Actinium Pharmaceuticals, Inc. 100.00 1 ['supplier']
MGNX MacroGenics, Inc. 100.00 2
LLY Eli Lilly and Company 100.00 2
RPRX Royalty Pharma plc 100.00 1 ['supplier']
SWKH SWK Holdings Corp 50.00 2
KURA Kura Oncology, Inc. 50.00 2
PRTC PureTech Health plc 50.00 2
RVMD Revolution Medicines, Inc. 50.00 2
MNPR Monopar Therapeutics Inc. 50.00 2
MRK Merck & Co., Inc. 50.00 2
TLX Telix Pharmaceuticals Limited 50.00 2
PTCT PTC Therapeutics, Inc. 50.00 2
NERV Minerva Neurosciences, Inc. 50.00 2
JNJ Johnson & Johnson 50.00 2
NUVL Nuvalent, Inc. 50.00 2
TAKEDA TAKEDA 50.00 2
ORANY ORANGE 50.00 2
CNSP CNS Pharmaceuticals, Inc. 50.00 2
View SNDX supply chain intel →

Explore the full interactive supply chain map for Syndax Pharmaceuticals, Inc..

Open SNDX supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map